These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3161370)

  • 1. [Blood serum sialic acids in the diagnosis of ovarian tumors].
    Makhova EE; Novikov AM; Bassalyk LS
    Akush Ginekol (Mosk); 1985 Mar; (3):54-5. PubMed ID: 3161370
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum lipid-bound sialic acid assay for detection of ovarian neoplasm].
    Chen SP
    Zhonghua Fu Chan Ke Za Zhi; 1983 Oct; 18(4):235-8. PubMed ID: 6675922
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lipid-bound serum sialic acids in the complex diagnosis of recurrences of cancer of the ovary].
    Bassalyk LS; Novikov AM; Makhova EE; Kozachenko VP
    Vestn Akad Med Nauk SSSR; 1985; (9):67-70. PubMed ID: 4060879
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical markers in ovarian cancer.
    Kiricuta I; Bojan O; Munteanu S
    Arch Geschwulstforsch; 1986; 56(1):35-8. PubMed ID: 3964031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary evaluation of the usefulness of determination of blood serum fucose and sialic acid level in women with genital tumors].
    Simm S; Markowska J; Tomaszkiewicz T; Herwichowska K
    Ginekol Pol; 1979 Nov; 50(11):957-63. PubMed ID: 544355
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in serum sialic acid levels in patients with ovarian tumors in the process of treatment].
    Travnikov ME; Novikov AM; Varazashvili LM; Bassalyk LS; Kozachenko VP
    Akush Ginekol (Mosk); 1990 Jul; (7):61-3. PubMed ID: 2240453
    [No Abstract]   [Full Text] [Related]  

  • 7. [Determination of N-acetylneuraminic acid for the differential diagnosis of cystic ovarian tumors].
    Donat H; Bernstein L; Schenk H; Erbstösser E; Rosé A
    Arch Geschwulstforsch; 1989; 59(2):113-20. PubMed ID: 2719531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness and potential pitfalls of sialic acid determination in sera of patients with ovarian tumors.
    Berra B; Rapelli S; Monticelli G; Fighetti MA; Della Mea I; Raspagliesi F; Di Re E; Ringhini R; Bombardieri E
    Int J Biol Markers; 1986; 1(1):39-46. PubMed ID: 3693972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of sialic acid and carcinoembryonic antigen as monitors of tumor burden among patients with carcinoma of the ovary.
    Silver HK; Karim KA; Salinas FA; Swenerton KD
    Surg Gynecol Obstet; 1981 Aug; 153(2):209-13. PubMed ID: 7244990
    [No Abstract]   [Full Text] [Related]  

  • 10. A case control study of glycoprotein status in ovarian carcinoma.
    Aranganathan S; Senthil K; Nalini N
    Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with gynecologic cancer by serum sialic acid determination.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Gynecol Oncol; 1989 May; 33(2):231-6. PubMed ID: 2703183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
    Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
    Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in serum fucose and sialic acid contents and the course of malignant ovarian neoplasms].
    Jaskulska T; Markowska J; Manyś G; Branowski M
    Nowotwory; 1983; 33(3):203-8. PubMed ID: 6664892
    [No Abstract]   [Full Text] [Related]  

  • 15. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
    Tang BJ; Li L; Xu J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of serum acute-phase reactants in patients with ovarian tumors.
    Warwas M; Dobryszycka W; Gerber J; Pietkiewicz A
    Neoplasma; 1981; 28(4):485-90. PubMed ID: 7290269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and choice of therapy in primary and metastatic ovarian tumors].
    Ermakova NA; Moiseenko VM; Orlova RV; Protsenko SA
    Vopr Onkol; 2001; 47(1):95-9. PubMed ID: 11317548
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor markers in epithelial ovarian cancer. Clinical applications.
    Hempling RE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.